Steris

STE on NYSE. STERIS sells infection-prevention products and services to healthcare and life science customers. Market value $20.6bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to March 2026.

Should I look at this?

Worth a closer look

Read what could go wrong

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
4.5%fair

For every $100 of what the whole company costs, it produced $4.55 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026
19.1×full

You pay 19.1 years of operating profit for the business. The average large US company costs around 18.

Return on capital
five annual reports to March 2026
7.1%five-year median

Each dollar kept in the business earns 7 cents a year. Above 10 is good.

Quality score: 89 of 100. Price score: 67 of 100. Our list needs 70 on quality and 60 on price.

$208.65 a share, 7% above its 1-year low

Over the past year the price has ranged from $195.14 to $269.44.

Dividend: 1.2% a year

Paid every year for at least 5 years

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

0.4
0.4
0.6
0.8
1.0
0.9
2022202320242025202612 monthsto Jun '26
Revenue
$4.2bn$4.5bn$5.1bn$5.5bn$5.9bn
Operating margin
11.3%17.4%16.3%15.9%18.6%
Debt to equity
0.470.510.510.310.27
Shares outstanding
0.10bn0.10bn0.10bn0.10bn0.10bn

Health checks

  • Free cash flow positive5 of 5 years
  • Accounting looks honest (Beneish)Nothing unusual
  • Financial strength (Piotroski)9 of 9
  • Profit backed by cash (accruals)Yes
  • Debt0.27× equity
  • Revenue growth, five yearsStrong, 13.8% a year
  • Buying back its own sharesRoughly flat

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $1.5 billion last quarter, up 7% on a year ago.
  • Profit: $200 million, up 13% on a year ago.
  • It keeps 19 cents of each $1 of sales as operating profit, up from 17 cents a year earlier.
  • Spare cash over the past 12 months: $926 million, up from $909 million.
  • 1% fewer shares than a year ago. Each share owns a bit more of the company.
  • Debt is $1.4 billion more than cash, down from $1.6 billion a year ago.
  • Sales grew on a year ago in each of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
September 2024$1.3bn
December 2024$1.4bn
March 2025$1.5bn
June 2025$1.4bn
September 2025$1.5bn
December 2025$1.5bn
March 2026$1.6bn
June 2026$1.5bn
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024$150m
December 2024$174m
March 2025$146m
June 2025$177m
September 2025$192m
December 2025$193m
March 2026$220m
June 2026$200m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
4 November 2026
Last annual report (10-K)
29 May 2026
Next quarterly (estimated, 10-Q)
6 November 2026

Who owns it

10 long-term investors we follow own it, up from 9 last quarter. 834 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

3 investors own more than 5%.

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 7 sold $10m, $1m of it under preset trading plans.

  • Sohi Mohsen
    Director
    Sold
    Date
    12 August 2026
    Shares
    4,058
    Price
    $235.78
    Value
    $956,795
  • Zangerle John Adam
    Sr. VP, Gen Counsel, and Sec.
    Sold
    under a preset trading plan
    Date
    15 June 2026
    Shares
    1,419
    Price
    $209.28
    Value
    $296,968
  • Carestio Daniel A
    President and CEO, Director
    Sold
    under a preset trading plan
    Date
    5 June 2026
    Shares
    1,374
    Price
    $212.00
    Value
    $291,288
  • Carestio Daniel A
    President and CEO, Director
    Sold
    under a preset trading plan
    Date
    4 June 2026
    Shares
    3,054
    Price
    $214.64
    Value
    $655,511
  • Breeden Richard C
    Director
    Sold
    Date
    2 June 2026
    Shares
    1,481
    Price
    $209.51
    Value
    $310,284
  • FELDMANN CYNTHIA L
    Director
    Sold
    Date
    5 March 2026
    Shares
    3,098
    Price
    $237.21
    Value
    $734,877
  • Madsen Julia
    Sr. VP and GM, Life Sciences
    Sold
    Date
    21 November 2025
    Shares
    5,008
    Price
    $262.00
    Value
    $1m
  • Tamaro Renato
    V.P. & Corporate Treasurer
    Sold
    Date
    18 November 2025
    Shares
    5,036
    Price
    $257.55
    Value
    $1m
  • Zangerle John Adam
    Sr. VP, Gen Counsel, and Sec.
    Sold
    Date
    11 November 2025
    Shares
    15,000
    Price
    $265.14
    Value
    $4m

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 29 May 2026, plus the 10-Q filed 7 Aug 2026 and 2 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

What changed in the risks this year

Companies must list what could hurt them each year. These are the parts that changed since last year’s report.

  • We could experience a failure of a key information technology system, process or site or a breach of information security, including a cybersecurity breach of one or more key information technology systems, networks, processes, associated sites or service providers; failure to manage these and other risks associated with the use of sophisticated technology could materially impact our business.

    Could happen
    Likewise, governments and regulatory bodies worldwide are actively developing new laws, regulations and ethical guidelines governing AI use, including the European Union’s Artificial Intelligence Act. Compliance with evolving and potentially inconsistent AI regulations across jurisdictions may be costly and complex. Failure to comply could result in significant penalties, restrictions on our use of AI, or reputational harm. The use of AI may also raise data privacy concerns, particularly if AI systems process sensitive health information subject to GDPR, HIPAA or other privacy regulations. If our competitors deploy AI technologies more effectively than we do, we may lose market share or be unable to maintain our competitive position. Failure to adequately manage AI-related risks could have a material adverse effect on our business, reputation, financial condition, and results of operations.
    Read more
  • Our operations are subject to regulations and permitting, which may be changed or amended by the relevant authorities, and which may limit or eliminate our current operations or increase the complexity, burden, or expense of compliance, and regulated materials or processes that we use in our operations are, and may in the future become subject to litigation.

    Could happen
    Similarly, we continue to invest in smart manufacturing to drive structural cost reduction in our facilities, including aligning work to more efficient manufacturing centers, implementing advanced manufacturing capabilities such as digital initiatives, automation and robots, and closing facilities that are not required to meet future capacity and work needs. Our success will depend on various factors, including our ability to either source or custom develop the necessary technology and components, and the digital transformation initiative’s cost-effectiveness, utility and competitive positioning. If our digital transformation initiative fails to develop as we expect, or progresses more slowly than expected, such failure to realize efficiencies and cost reduction benefits could adversely impact our financial condition and results of operations.
    Read more
  • The effects of geopolitical instability may adversely affect us and create significant risks and uncertainties for our business, with the ultimate impact dependent on future developments, which are highly uncertain and unpredictable.

    Could happen
    Furthermore, the U.S. and other countries have announced and enacted changes, and planned changes, to international trade policy, including increasing tariffs on imports, and potentially renegotiating or terminating existing trade agreements. The international trade environment is highly dynamic, and such changes, and retaliatory responses thereto, continue to evolve. Tariffs, trade restrictions and other changes to international trade policies may result in increased production costs and product pricing, supply chain disruptions, limited access to end markets, lower profitability, increasing inability of consumers and Customers to pay, reduced consumer and Customer demand, economic slowdowns and recessions and uncertainty related to planning long-term investments and strategies, and may have other competitive effects, including those exacerbated by competitors with different supply chain footprints, each of which could have a material adverse effect on our business. In addition, the United States-Mexico-Canada Agreement (“USMCA”) requires a formal six-year joint evaluation of the agreement. The first such review is expected to commence on July 1, 2026, the sixth anniversary of the agreement's entry into force. The U.S. has solicited feedback from the trading community regarding the operation of the USMCA, and the joint review could result in changes, including, for example, the processes by which goods qualify for preferential treatment, the tariffs applicable to products or other restrictions on the movement of goods within the region under the USMCA. Changes to the USMCA could adversely affect our manufacturing operations and those of our suppliers in Canada and Mexico and impact our ability to manufacture and market products or source materials at competitive prices, which could have a material adverse effect on our financial condition and results of operations. We cannot predict the ultimate scope, duration, or impact of current or future tariff measures, changes to existing trade agreements, such as the USMCA, or the imposition of other trade restrictions.
    Read more
  • STERIS has incurred and expects to incur significant transaction and related costs in connection with strategic transactions, which may be in excess of those anticipated.

    Could happen
    STERIS may not achieve expected returns and benefits in connection with dispositions, which may require continued involvement in a divested business, such as through transition service agreements, guarantees, indemnities or other financial obligations. Under these arrangements, the performance of the divested business, or other conditions outside our control, could affect our future financial results. The costs described above, as well as other unanticipated costs and expenses, could have a material adverse effect on the financial condition and operating results.
    Read more
  • Our operations are subject to regulations and permitting, which may be changed or amended by the relevant authorities, and which may limit or eliminate our current operations or increase the complexity, burden, or expense of compliance, and regulated materials or processes that we use in our operations are, and may in the future become subject to litigation.

    Although we believe we have valid defenses to such claims, there can be no assurance that we will prevail on the merits, as the outcome of trials before juries and other aspects of litigation can be highly unpredictable, and, as a result, we have chosen to pursue a settlement process with respect to certain pending cases in Illinois. Pursuant to binding confidential settlement agreements entered into in March and October 2025, we agreed to pay up to approximately $48.2 million to resolve substantially all of the claims for personal injury against a subsidiary related to EO exposure that are pending in the Circuit Court of Cook County, Illinois. A claims process regarding confidential settlement agreements is ongoing and subject to final court approval. Furthermore, some claims would be subject to further litigation if certain terms of the applicable settlement agreements are not fulfilled and we exercise our walkaway rights. Please refer to Note 12 to our consolidated financial statements titled “Commitments and Contingencies” for further information.
    Read more

Read it in the annual report

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.